Keywords: genentech, 1st-qtr, profit, jumps, despite, lackluster, avastin
Genentech's 1st-qtr 2007 profit jumps 12%, despite lackluster Avastin sales
Article | 21 April 2008
US biotechnology giant Genentech's first-quarter 2008 profit was slightly ahead of Wall Street expectations, rising 11.9% year-on-year, to $790.0 million, or $0.74 per share, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
